Daewoong Pharmaceutical about to launch first domestic generic in the U.S.
‘Daewoong Meropenem Inj’ will first enter the U.S. as a Korean generic product.
On the 5th, Daewoong Pharmaceutical(CEO Jong-ok Lee) announced ‘Daewoong Meropenem Inj,’ a carbapenem-type antibiotic, has acquired approval from the US Food and Drug Administration(FDA).
The approval was finalized ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
